Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid

Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA). However, the efficacy and safety of FF in patients with cirrhosis remain unclear. To evaluate the efficacy and safety of additional FF ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Dawei, Guo, Guanya, Liu, Yansheng, Zheng, Linhua, Jia, Gui, Deng, Juan, Sun, Ruiqing, Wang, Xiufang, Guo, Changcun, Shang, Yulong, Han, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701475/
https://www.ncbi.nlm.nih.gov/pubmed/36213941
http://dx.doi.org/10.1002/hep4.2103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701475/
https://www.ncbi.nlm.nih.gov/pubmed/36213941
http://dx.doi.org/10.1002/hep4.2103

Ejemplares similares